Neuromedin U is a hypothalamic peptide involved in energy homeostasis and stress responses. The peptide, when administered intracerebroventricularly (i.c.v.), decreases food intake and body weight while increasing body temperature and heat production. We examined the effect of i.c.v. administered neuromedin U on plasma catecholamines with regard to the brain prostanoid using anesthetized rats.
Introduction
Neuromedin U is a peptide initially isolated from porcine spinal cord and named due to its strong contractile properties in the uterus (Minamino et al., 1985) . The peptide was later identified in the brain, spinal cord and intestine of other species (O'Harte et al., 1991; Kage et al., 1991; Austin et al., 1994) . Rat and mouse neuromedin U consists of 23 amino acids and their C-terminal regions, which are essential for the peptide's activity, are highly conserved compared to other species (Conlon et al., 1988; Minamino et al., 1988) . Neuromedin U-like immunoreactivity is found in the spinal cord, several brain regions including the hypothalamus, pituitary and thyroid glands in addition to the gastrointestinal and urogenital tracts (Brighton et al., 2004) . While several peripheral activities such as contraction of smooth muscle and blood vessels and hypertensive effects have been described for neuromedin U (Minamino et al., 1985; Sumi et al., 1987; Gardiner et al., 1990) , its role in the central nervous system remains poorly understood.
Neuromedin U-like immunoreactivity and mRNA in the central nervous system are abundant in nuclei of the brain stem and hypothalamus. Within the hypothalamus, neuromedin U-like immunoreactive cell bodies and mRNA expression are restricted to the arcuate nucleus and median eminence (Ballesta et al., 1988; Howard et al., 2000) .
The paraventricular, ventromedial and dorsomedial nuclei receive dense innervation of neuromedin U immunoreactive fibers (Ballesta et al., 1988) . Neuromedin U receptor subtype 2 mRNA is also demonstrated in the hypothalamus including paraventricular nucleus (Guan et al., 2001) . Centrally administered neuromedin U has been reported to decrease food intake and body weight in free-feeding rats (Howard et al., 2000;  furegrelate and (+)-S-145 dissolved in sterile saline were intracerebroventricularly (i.c.v.) administered in a volume of 5 µl/animal using a 10-µl Hamilton syringe. In the case of using blocking reagents, neuromedin U was i.c.v. administered 30 min after the application of indomethacin-Na and 60 min after the application of furegrelate or (+)-S-145, due to their slightly elevating effects on the basal plasma levels of catecholamines. Each animal also received only one dose of blocking reagents (or vehicle).
All experiments were conducted in compliance with the guiding principles for the care and use of laboratory animals approved by Kochi University.
Measurement of plasma catecholamines
Blood samples (250 µl) were collected through an arterial catheter and were preserved on ice during experiments. Plasma was prepared immediately after the final sampling. Catecholamines in the plasma were extracted by the method of Anton and Sayre (1962) with a slight modification and were assayed electrochemically with high performance liquid chromatography (HPLC) (Shimizu et al., 2004) . Briefly, after centrifugation, the plasma (100 µl) was transferred to a centrifuge tube containing 30 mg of activated alumina, 2 ml of twice deionized water, 1 ml of 1.5 M Tris Buffer (pH 8.6) containing 0.1 M disodium EDTA and 1 ng of 3,4-dihydroxybenzylamine as an internal standard. The tube was shaken for 10 min and the alumina was washed three times with 4 ml of ice-cold twice deionized water. Then, catecholamines adsorbed onto the alumina were eluted with 300 µl of 4% acetic acid containing 0.1 mM disodium EDTA. A pump (EP-300: Eicom, Kyoto, Japan), a sample injector (Model-231XL;
Gilson, Villiers-le-Bel, France) and an electrochemical detector (ECD-300: Eicom) equipped with a graphite electrode were used with HPLC. Analytical conditions were as follows: detector, +450 mV potential against an Ag/AgCl reference electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); mobile phase, 0.1 M NaH 2 PO 4 -Na 2 HPO 4 buffer (pH 6.0) containing 50 mg/l disodium EDTA, 0.75 g/l 1-octanesulfonate sodium and 15% methanol at a flow of 0.18 ml/min; injection volume, 40 µl. The amount of catecholamines in each sample was calculated using the peak height ratio relative to that of 3,4-dihydroxybenzylamine. By this assay, coefficients of variation for intra-and inter-assay were 3.0% and 3.7%, respectively, and 0.5 pg of noradrenaline and adrenaline was accurately determined.
Treatment of data and statistics
All values are expressed as the means±S.E.M. of the net changes above the respective basal values. The data were analyzed by repeated-measure analysis of variance (ANOVA), followed by post-hoc analysis with the Bonferroni method for comparing a control to all other means (Figs. 1-4) . When only two means were compared, an unpaired Student's t-test or Welch's t-test was used (Fig. 5) . P values less than 0.05 were taken to indicate statistical significance.
Compounds
The following drugs were used: neuromedin U (Peptide Institute, Osaka, Japan); 
Results

Effect of neuromedin U on plasma catecholamines
I.c.v. administered vehicle (10 µl saline/animal) and blood sampling for 5 times for 60 min had no effect on the basal plasma levels of either adrenaline or noradrenaline ( Intravenous administration of neuromedin U (0.5 nmol/animal) had no effect on plasma levels of both catecholamines (data not shown).
Effect of indomethacin (an inhibitor of cyclooxygenase) on the centrally administered neuromedin U-induced elevation of plasma catecholamines
Treatments with vehicle-1 (5 µl saline/animal, i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect on the basal plasma levels of adrenaline and noradrenaline. Pretreatment with indomethacin [1.2 µmol (500 µg)/animal, i.c.v.] had no effect on the basal plasma levels of catecholamines (Fig. 2) .
Indomethacin [0.6 and 1.2 µmol (250 and 500 µg)/animal, i.c.v.] significantly reduced the neuromedin U (0.5 nmol/animal, i.c.v.)-induced elevation of plasma adrenaline, while the reagent had no effect on the neuromedin U-induced noradrenaline response (Fig. 2) .
Effect of furegrelate (an inhibitor of thromboxane A 2 synthase) on the centrally administered neuromedin U-induced elevation of plasma catecholamines
Treatments with vehicle-1 (5 µl saline/animal, i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect on the basal plasma levels of adrenaline and noradrenaline. Pretreatment with furegrelate [1.8 µmol (500 µg)/animal, i.c.v.] had no effect on the basal plasma levels of both catecholamines ( the reagent had no effect on the neuromedin U-induced noradrenaline response (Fig. 3) .
Effect of (+)-S-145 (a blocker of prostanoid TP receptors) on the centrally administered neuromedin U-induced elevation of plasma catecholamines
Pretreatment with (+)-S-145 [625 nmol (250 µg)/animal, i.c.v.] had no effect on the basal plasma levels of adrenaline and noradrenaline (Fig. 4) .
(+)-S-145 [250 and 625 nmol (100 and 250 µg)/animal, i.c.v.] dose-dependently reduced the neuromedin U (0.5 nmol/animal, i.c.v.)-induced elevation of plasma adrenaline, while the reagent had no effect on the neuromedin U-induced noradrenaline response (Fig. 4) .
Effect of acute bilateral adrenalectomy on the centrally administered neuromedin U-induced elevation of plasma catecholamines
The basal plasma levels of noradrenaline were not influenced by bilateral adrenalectomy, while the basal adrenaline level was effectively, but not significantly, reduced by this procedure (Fig. 5 ).
Bilateral adrenalectomy abolished the neuromedin U (0.5 nmol/animal, i.c.v.)-induced elevation of plasma adrenaline, while the procedure largely had no effect on the neuromedin U-induced noradrenaline response (Fig. 5 ).
Discussion
Plasma adrenaline is mainly secreted from adrenal medulla (adrenalinecontaining cells), while plasma noradrenaline reflects not only the release from sympathetic nerves but also the secretion from the adrenal medulla (noradrenalinecontaining cells) (Verhofstad et al., 1985; Edwards et al., 1996; Suzuki and Kachi, 1996; Vollmer et al., 2000; Yamaguchi-Shima et al., 2007) . In the present study, i.c.v.
administered neuromedin U elevated plasma adrenaline but had little effect on plasma noradrenaline in rats. Since intravenously administered neuromedin U had no effect on the plasma catecholamines, the peptide seems to act on the central nervous system, thereby activating the central adrenomedullary outflow in rats.
We and 315±23 pg/ml (n=28), respectively. Other conditions were the same as those of Fig. 1 . The actual values for adrenaline and noradrenaline at 0 min were 316±53 and 413±49 pg/ml in the vehicle-1-pretreated group (n=12); 411±68 and 246±38 pg/ml in the indomethacin (0.6 µmol/animal)-pretreated group (n=5); 390±157 and 261±88 pg/ml in the indomethacin (1.2 µmol/animal)-pretreated group (n=10), respectively. 
